康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 01-15 16:00:00 EST

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO","defaultTab":"news","newsList":[{"id":"2608306028","title":"国信证券：小核酸CXO行业景气度持续攀升 迈入临床兑现与商业化加速阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2608306028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608306028?lang=zh_cn&edition=full","pubTime":"2026-02-02 14:30","pubTimestamp":1770013847,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，小核酸CXO作为小核酸药物产业的核心支撑，受益于技术突破与商业化加速，行业景气度持续攀升。小核酸CXO行业同步进入发展快车道，形成“研发服务-中试放大-商业化生产”的CRDMO全链条服务体系。报告中称，小核酸药物正迎来全球范围内的蓬勃发展期，已从技术验证阶段迈入临床兑现与商业化加速阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0188","BK0276","002736","BK0028","BK0183"],"gpt_icon":0},{"id":"2606930347","title":"国联民生证券：全球CXO行业强势复苏 2026年有望延续高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2606930347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606930347?lang=zh_cn&edition=full","pubTime":"2026-01-28 15:58","pubTimestamp":1769587104,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联民生证券发布研报称，全球生物科技及药企投融资活动及交易需求在2025年显著回暖，创新药新技术平台蓬勃发展，驱动CXO行业下游需求全面复苏，行业景气度有望将、在2026年延续。中国市场IND数量同比增长19%，BD交易金额同比高增，国内创新药市场活力充沛，为CXO行业提供持续动能。国内临床CRO明确拐点，泰格医药受益行业复苏中国CRO市场于2025年重回增长轨道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601456","01456","CXO","BK1564","BK1147","161027","BK0276"],"gpt_icon":0},{"id":"2605449493","title":"近五成生物医药公司业绩预喜 多家CXO企业表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2605449493","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605449493?lang=zh_cn&edition=full","pubTime":"2026-01-23 08:24","pubTimestamp":1769127883,"startTime":"0","endTime":"0","summary":"南方财经1月23日电，据中证报，截至1月22日，按照申万一级行业划分，已有逾50家生物医药企业披露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括CDMO和CRO）公司业绩表现亮眼。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628152649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["161726","399441","BK4585","LABU","BK4588","CXO"],"gpt_icon":0},{"id":"2603955152","title":"西南证券：CXO行业关注新分子的成长性与国内景气度修复的传导","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603955152?lang=zh_cn&edition=full","pubTime":"2026-01-16 10:37","pubTimestamp":1768531037,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，CXO板块持续关注：1）全球市场多肽、偶联药物、寡核酸等新分子对R、D、M外包持续注入的增长动能；2）地缘风险不确定性出清后的反转与板块情绪面改善；3）国内市场景气度修复、创新药研发需求的传导；4）AI赋能的药物研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0188","BK0276","BK0028","600369","BK0012","BK0183"],"gpt_icon":0},{"id":"2603681308","title":"智通港股解盘 | 担忧地缘政治多数黄金股创历史新高 利好推动CXO全线走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603681308?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:42","pubTimestamp":1768308157,"startTime":"0","endTime":"0","summary":"恒指不敢持续发力，因为还是有担忧情绪，当地时间12日，美国国务院在网站上发布信息，要求美国公民立即离开伊朗。智通1月金股——紫金黄金国际也涨超5%，同样创出了上市以来的新高。中方将坚定维护自身正当合法权益。这对中国创新药企是好消息。近日，研究服务业务首付款和总付款金额再创新高，去年合作项目的潜在里程碑付款总额高达40亿美元以上。紫金矿业巨龙铜矿项目二期全面达产后，将新增日处理20万吨矿石的产能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1546","CXO","LU2125910500.SGD","BK1583","BK1161","LU0052750758.USD","BK1205","HK0000252152.HKD","02315","LU2045819591.USD","LU0708995583.HKD","SGXZ86797644.SGD","HK0000500386.USD","BK1141","BK1117","SGXZ62798434.SGD","LU2213484517.USD","HK0000252160.HKD","LU0320764599.SGD","02359","159562","BK1198","LU1046422090.SGD","LU2242644610.SGD","BK1522","02259","01072","LU2543165471.USD","LU0593848301.USD"],"gpt_icon":1},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854186?lang=zh_cn&edition=full","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CXO","BK4139","02509","06160","ONC","01167","01541","00013","BK4526","BK4585","01801","BMS"],"gpt_icon":0},{"id":"2594286909","title":"国信证券：美国医药供应链新规出台 关注CXO板块投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2594286909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594286909?lang=zh_cn&edition=full","pubTime":"2025-12-25 09:40","pubTimestamp":1766626821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，美国国会近日通过2026财年国防授权法案，其中纳入修订版《生物安全法案》相关条款，中国创新药产业长期竞争力仍受看好。建议关注CXO板块，并留意创新药海外临床进展。国信证券主要观点如下：《生物安全法案》获参、众议院通过，关注CXO板块投资机会美国时间12月17日，美国参议院以77票赞成、20票反对的表决结果，通过2026财年国防授权法案。法案后续将提交白宫，待美国总统签署生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK0183","09939","CXO","BK1515","002736","BK0276","BK0028","BK1161","BK0188"],"gpt_icon":0},{"id":"2593657109","title":"医药外包概念股逆市受压 康龙化成(03759)跌4.14% 机构指美生物安全法案对华CXO企业经营影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2593657109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593657109?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:06","pubTimestamp":1766383579,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股逆市受压，截至发稿，康龙化成 跌4.14%，药明生物跌3.75%，药明康德跌2.89%，昭衍新药跌2.67%，泰格医药跌2.07%，金斯瑞生物科技跌1.36%。招银国际表示，MSCI中国医疗指数2025年初至今累计上涨51.9%，跑赢MSCI中国指数24.3%。近期，医药板块有所回调。政策端方面，《生物安全法案》虽已签署生效，但鉴于其未波及Medicaid和Medicare的采购且对关联方定义明确，以及中国CXO美国行政机构收入占比较小，该机构预计该法案对中国CXO企业实质经营影响有限。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","02359","03759","HK0000306685.HKD","LU0516423091.SGD","LU0516423174.USD","LU3063872942.SGD","BK1161","LU0359201612.USD","LU0456846285.SGD","LU0327786744.USD","300759","LU0348825331.USD","LU0417516738.SGD","LU0823426308.USD","LU1242518931.SGD","09939","BK1583","BK1141","LU2125910500.SGD","BK1589","02269","BK0216","HK0000306701.USD","SG9999002562.SGD","SG9999002463.SGD","LU0819121731.USD","BK1576","LU0320764599.SGD","159938","LU0359202008.SGD","LU0326950275.SGD","LU0140636845.USD","LU0708995583.HKD","LU0051755006.USD","BK1574","LU1046422090.SGD","01548","03347","HK0000320223.HKD","LU0572944931.SGD","LU1880383366.USD","CXO","LU0516422440.USD","BK1610","LU0417516902.SGD","LU2039709279.SGD","HK0000320264.USD","06127","LU0348735423.USD"],"gpt_icon":0},{"id":"2592139047","title":"医药外包概念普遍走高 药明生物(02269)涨6.11% 机构看好看好CXO在业绩和估值端迎来双重修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139047","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139047?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:26","pubTimestamp":1766111188,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念普遍走高，药明生物 涨6.11%，凯莱英升5.52%，康龙化成升4.69%，泰格医药升3.8%，维亚生物升3.72%，药明康德涨3.32%。世纪证券此前研报指出，本周NDAA法案落地，地缘风险趋于缓和。CXO业绩和新增订单开始好转，本周市场开始关注临床前安评试验资产食蟹猴。该机构认为CXO作为创新药产业链上游，行业经历过完整周期，有望受益于国产创新药竞争力提升带来的景气度回升，看好CXO在业绩和估值端迎来双重修复。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66afc1ba6d0078bbc724c4259409298b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","SG9999002463.SGD","LU0417516902.SGD","CXO","LU0051755006.USD","01873","IE00B0JY6N72.USD","LU2125910500.SGD","06821","03347","LU0348825331.USD","LU1794554557.SGD","LU1880383366.USD","LU0181495838.USD","BK1583","LU0516422440.USD","LU0708995583.HKD","LU1242518931.SGD","LU0140636845.USD","LU3063872942.SGD","LU2242644610.SGD","BK1589","LU1046422090.SGD","03759","BK1161","SG9999002562.SGD","BK1574","LU1720050803.USD","BK1610","LU0516422952.EUR","LU0516423091.SGD","LU0456827905.SGD","BK1191","LU0043850808.USD","02269","159938","LU0348735423.USD","02359","LU0819121731.USD","LU0823426480.USD","LU0516422366.SGD","LU2045819591.USD","LU0359201612.USD","LU0039217434.USD","LU0516423174.USD","BK1521","BK1576","09939","LU0979878070.USD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2592588924","title":"华泰 | 医药深度：CXO拐点已至，新周期启航","url":"https://stock-news.laohu8.com/highlight/detail?id=2592588924","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592588924?lang=zh_cn&edition=full","pubTime":"2025-12-18 07:50","pubTimestamp":1766015400,"startTime":"0","endTime":"0","summary":"CXO行业外部扰动因素已边际改善，伴随海外降息、国内复苏、叠加产业升级三重驱动，行业已开启新一轮高景气周期。我们看好CXO板块后续有望迎来业绩与估值的戴维斯双击，推荐外需型且具备新分子布局优势的龙头。药企在选择CXO供应商时亦更加谨慎（重点关注资金链、服务质量、","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649838559&idx=2&sn=a93572ab318bad055faa1dbc754a53ed&chksm=89d48d7fdc9079ae45d28fca227aa45f5a7110cc82b97ead2a34f76b0590b271a9c4c771a009&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1515","09939","BK1574","CXO","BK1161","159938"],"gpt_icon":0},{"id":"2590393913","title":"招银国际：2025医保目录公布延续支持创新 料CXO业下半年修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2590393913","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590393913?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:03","pubTimestamp":1765245827,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，2025年版基本医保目录以及首版商保目录发布，延续支持创新，料CXO行业有望在下半年迎来业绩修复。推荐买入三生制药(01530)、固生堂(02273)、药明合联(02268)、巨子生物(02367)、信达生物(01801)、中国生物制药(01177)。报告表示，多家企业的核心创新品种获纳入医保。该行认为，宏观环境及老龄化的挑战下，医保收支压力仍在，关注国家集采续约。尽管首版商保目录短期对于产品销售的拉动有限，由于商业保险的规模不大，认为商保目录的意义重大，或将开启中国商业医疗保险扩容的道路，成为中国多元化支付体系发展开端。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268","BK1141","BK1191","LU2097828631.EUR","BK1593","LU0502904849.HKD","02367","LU2328871848.SGD","BK1161","IE00BZ08YR35.GBP","LU2097828714.EUR","LU2097828474.EUR","BK1521","BK1589","01530","BK1207","01177","LU2097828805.USD","BK1219","IE00BZ08YS42.EUR","LU2488822045.USD","IE00BZ08YT58.USD","BK1583","LU0455707207.USD","LU2242644610.SGD","LU1969619763.USD","02273","BK1515","SG9999014674.SGD","01801","HK0000165453.HKD","CXO","SG9999004311.SGD","LU2097828557.USD"],"gpt_icon":0},{"id":"2585363594","title":"港股概念追踪|创新药企业绩普遍增长  上游CXO行业调整基本完成（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2585363594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585363594?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:12","pubTimestamp":1763943133,"startTime":"0","endTime":"0","summary":"国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1141","LU0708995583.HKD","LU3063872942.SGD","BK1521","CXO","159992","LU0823426308.USD","LU0819121731.USD","SG9999002463.SGD","LU1794554557.SGD","LU0823426480.USD","06821","LU0417516902.SGD","BK1576","LU1046422090.SGD","02359","LU0181495838.USD","LU0326950275.SGD","LU2045819591.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU2125910500.SGD","LU2039709279.SGD","BK1583","LU0348735423.USD","LU0359202008.SGD","BK1161","LU0456827905.SGD","BK1610","SG9999002562.SGD","LU1242518931.SGD","LU0051755006.USD","LU0516423091.SGD","LU2242644610.SGD","LU0417516738.SGD","LU0043850808.USD","LU0588546209.SGD","02269","BK1574","LU0039217434.USD","BK1191","LU0348825331.USD","LU1880383366.USD","LU0140636845.USD","LU0979878070.USD","LU1688375341.USD","LU0052750758.USD","BK1589","LU1242518857.USD"],"gpt_icon":0},{"id":"2585435821","title":"中信建投：CXO行业调整基本完成 重点关注出海能力强的CDMO企业及临床CRO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585435821?lang=zh_cn&edition=full","pubTime":"2025-11-24 07:36","pubTimestamp":1763940962,"startTime":"0","endTime":"0","summary":"CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。从国际比较优势看，中国具备人口与内需优势、制造与供应链优势，同时创新能力快速提升，中国资产出海数量也持续提升。2025年下半年我们重点关注的是药品和耗材集采政策优化、多元化支付及医疗服务价格改革。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK0276","CXO","601066","CDMO"],"gpt_icon":0},{"id":"2585448396","title":"海纳医药转战港股IPO背后：CXO依赖症、现金流失血、大客户频变","url":"https://stock-news.laohu8.com/highlight/detail?id=2585448396","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585448396?lang=zh_cn&edition=full","pubTime":"2025-11-23 15:28","pubTimestamp":1763882880,"startTime":"0","endTime":"0","summary":"　　冲刺A股创业板折戟、被上市公司成都先导并购未果后，近日南京海纳医药科技股份有限公司递交招股书转道港股市场，开启三年内的第三次资本化尝试。　　证券之星注意到，这家号称“药物技术转移CXO服务排名第二”的公司，正面临经营性现金流转负、应收账款激增，毛利率承压的多重考验。这背后，海纳医药高度依赖CXO业务，陷入“增收不增利”困境，频繁变动的大客户更凸显业务结构的不稳定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-11-23/doc-infykswe4862812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","BK1161","BK1574","159938","159399","BK1515","09939"],"gpt_icon":0},{"id":"2583554140","title":"新股前瞻|港股再迎CXO新势力，海纳医药“含金量”几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554140","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583554140?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:21","pubTimestamp":1763022073,"startTime":"0","endTime":"0","summary":"近日，据港交所披露，南京海纳医药科技股份有限公司向港交所主板提交上市申请书，中金公司为其独家保荐人。截至2025年上半年末，海纳医药仍有398个正在进行的CXO项目。除CXO服务外，海纳医药还拥有自主立项的专有管线。于往绩记录期间，海纳医药签订了67份药物技术转让协议。尽管具有一定的成长性，但与国内聚焦创新药的CXO龙头企业相比，海纳医药主要布局仿制药领域，技术门槛相对较低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","BK1161","CXO","BK1574","159938"],"gpt_icon":0},{"id":"2582323536","title":"海纳医药港股IPO：上半年收入、净利润双下滑业绩增长乏力 高度依赖CXO服务 \"多次开发\"模式可持续性存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2582323536","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582323536?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:06","pubTimestamp":1762934760,"startTime":"0","endTime":"0","summary":"南京海纳医药科技股份有限公司于2025年11月7日正式向港交所递交主板上市申请，这是公司继2023年创业板IPO折戟和2025年与成都先导并购谈判失败后，三年内第三次尝试登陆资本市场。　　作为一家成立24年的医药研发与制造一体化企业，海纳医药凭借“CXO+MAH”业务模式在细分领域占据一席之地。　　海纳医药的营收增长已显疲态。　　海纳医药的收入严重依赖CXO服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-12/doc-infxcqhz3531514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","159776"],"gpt_icon":0},{"id":"2582981337","title":"招银国际：CXO企业下半年业绩或复苏 看好中国生物制药及药明合联等","url":"https://stock-news.laohu8.com/highlight/detail?id=2582981337","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582981337?lang=zh_cn&edition=full","pubTime":"2025-11-11 14:24","pubTimestamp":1762842240,"startTime":"0","endTime":"0","summary":"招银国际发布研报称，MSCI中国医疗指数年初至今累计升幅达59.5%，跑赢MSCI中国指数24%，至近期医药板块出现回调，10月初起回落约10%，认为部分股份估值较低，仍具吸引力，看好三生制药、固生堂、巨子生物、药明合联、信达生物及中国生物制药，均予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-11-11/doc-infwzfae7375727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","IE00BZ08YR35.GBP","LU2488822045.USD","BK1191","01177","02268","CXO","BK1521","IE00BZ08YS42.EUR","SG9999014674.SGD","IE00BZ08YT58.USD","HK0000165453.HKD","BK1589","BK1141"],"gpt_icon":0},{"id":"2582823841","title":"【券商聚焦】招银国际：CXO行业有望在下半年迎来业绩修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582823841","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582823841?lang=zh_cn&edition=full","pubTime":"2025-11-10 13:30","pubTimestamp":1762752642,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，MSCI中国医疗指数2025年初至今累计上涨59.5%，跑赢MSCI中国指数24.0%。近期，医药板块有所回调，该机构认为部分低估值个股具备吸引力。叠加美国降息，CXO行业有望在2H25E迎来业绩修复。辉瑞管理层表示即将公布707的完整研发计划。此次医保谈判结果预计12月初公布。本轮集采的平均价格降幅并未公布。该机构认为仿制药仍将长期维持较低利润率水平。但该机构认为，本土市场的表现仍是重要的业绩变量。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969308","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328277881.USD","LU2097828631.EUR","LU1251922891.USD","LU2097828805.USD","BK1521","LU0327786744.USD","LU1951186391.HKD","09926","LU1152091168.USD","LU0039217434.USD","LU0516422440.USD","LU0417516902.SGD","LU0561508036.HKD","06185","01877","01093","01177","LU0456827905.SGD","01801","BK1576","LU1960683339.HKD","LU0348767384.USD","LU0634319403.HKD","LU1770034418.SGD","LU0417516738.SGD","LU0348825331.USD","LU0540923850.HKD","LU1993786604.SGD","LU0856984785.SGD","LU1807302812.USD","IE0008368742.USD","IE00B0JY6N72.USD","LU0572944931.SGD","BK1161","02616","LU1969619763.USD","LU2476274720.SGD","LU0456846285.SGD","LU2242644610.SGD","LU2097828714.EUR","LU2476274308.USD","LU1226288253.USD","LU1794554557.SGD","09688","09995","CXO","02269","06160","LU0823426480.USD","02142"],"gpt_icon":0},{"id":"2571142633","title":"招银国际：美国针对创新药将加征关税预期对CXO影响有限 推荐买入三生制药(01530)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2571142633","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571142633?lang=zh_cn&edition=full","pubTime":"2025-09-30 15:56","pubTimestamp":1759219015,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，预期中美创新合作将持续，中国国内创新研发需求回暖。叠加美国降息，CXO 行业有望在下半年迎来业绩修复。而美国针对创新药将加征关税，预期对CXO影响有限。特朗普于9月25日宣布，除非制药商正在美国建设工厂，否则从10月1日开始，专利药品将面临100%的关税。由于多家跨国药企已有美国建厂计划，因此或将不受影响。推荐买入三生制药、巨子生物、药明合联、固生堂、中国生物制药、信达生物 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1515","SG9999004311.SGD","BK1191","BK1161","01530","159992","LU1969619763.USD","LU0502904849.HKD","06978","IE00BZ08YR35.GBP","BK1207","LU0455707207.USD","CXO","LU2097828474.EUR","SG9999014674.SGD","LU2488822045.USD","BK1574","BK1141","IE00BZ08YT58.USD","02273","01801","BK1589","02268","LU2242644610.SGD","IE00BZ08YS42.EUR","LU2328871848.SGD","LU2097828805.USD","BK1583","01177","BK1521","LU2097828557.USD","LU2097828714.EUR","LU2097828631.EUR","02367","BK1219"],"gpt_icon":0},{"id":"2571806873","title":"小摩：续列药明康德(02359)为CXO首选股 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2571806873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571806873?lang=zh_cn&edition=full","pubTime":"2025-09-29 13:52","pubTimestamp":1759125138,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，继续列药明康德(02359)为中国CXO行业的首选股，指出该公司是中国收入规模最大的合同研究开发与生产组织，看好其业务基本面，认为小分子CRDMO领域竞争相对温和，同时药明TIDES业务增长动力持续强劲，维持“增持”评级，目标价138港元。小摩日前参与药明康德的2025年投资者日，适逢美国总统特朗普宣布计划自10月1日起对进口品牌药及专利药征收100%关税，除非相关药厂已在美国动工兴建生产设施。小摩预期这次药品关税政策对药明康德等中国CDMO企业不会构成直接影响，因客户通常负责支付关税，而且药明康德正在扩充其美国产能，以满足客户对本地化生产的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","CXO","603259"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}